Inhibiton Therapeutics' Researcher to Present at American Association for Cancer Research Annual...

CENTENNIAL, Colo. -- Inhibiton Therapeutics, Inc. (OTCBB: IHBT) announced today that the principal researcher for its ICA-1 compound, Dr. Mildred Acevede-Duncan, will present an abstract of the ICA-1 compound at the American Association for Cancer Research ("AACR") Annual Meeting in San Diego, California

The ICA-1 compound has demonstrated more exacting specificity of protein kinase C-iota and not of proteins that are closely related to PKC-iota. These results demonstrate greater promise for the development of a targeted therapy. Research being funded by the Company has shown that the ICA-1 compound has been effective in laboratory in-vitro testing in various cancer cell lines. This research has demonstrated that inhibition of the enzyme protein kinase C-iota is a promising means to prevent and treat certain cancers through development of a targeted therapy.

Previously announced laboratory testing has shown that ICA-1 was effective in blocking BE(2)C neuroblastoma cells finding and that lower concentrations of ICA-1 were more efficacious in inhibiting the proliferation of 64% and 53% of the neuroblastoma cells when compared to control groups. The effects of ICA-1 on breast cancer cells have also obtained promising results. ICA-1 was effective in reducing the proliferation of MDA-MB-468 breast cancer cells by 83% compared to controls when incubated with the drug for 48 hours at clinical concentrations. For MCF-7 breast cancer cells, ICA-1 was effective in reducing the proliferation by 32% compared to controls when treated with the drug for 24 hours.

These results indicate that ICA-1 has promising results for further in-vitro studies as well as future in-vivo studies for the potential treatment of both neuroblastoma and breast cancer.

Inhibiton Therapeutics, Inc. is a nominally capitalized development-stage company focused on biotechnology research, development and potential commercialization of technologies and products for new cancer therapeutic agents and cancer-fighting drugs called targeted therapies. The initial focus of the Company's research is a protocol to investigate the effect of PKC isozymes on the regulation of various cancer cells including brain and breast cancer. Inhibiton began funding this research in September 2004.